ASKA Pharmaceutical Holdings Co.,Ltd.
Supplementary Materials for the Financial Summary for the Third Quarter of the Fiscal Year Ending March 2026
Net sales of 54.4 billion yen, a 9.1% increase year-over-year. Operating income was 4.9 billion yen, a 10.6% decrease year-over-year. Full-year earnings guidance forecasts net sales of 71.0 billion yen and operating income of 6.0 billion yen.
Key Figures
- Net Sales (Q3): 54.4 billion yen (9.1% increase YoY)
- Operating Income (Q3): 4.9 billion yen (10.6% decrease YoY)
- Full-year Net Sales Forecast: 71.0 billion yen (10.7% increase YoY)
AI要約
Overview of Performance
Consolidated net sales for the third quarter of the fiscal year ending March 2026 reached 54.4 billion yen, a 9.1% increase year-over-year, marking a record high. This was driven by steady performance in domestic operations and increased contributions from overseas business. Conversely, operating income was 4.9 billion yen, a 10.6% decrease year-over-year. The primary cause of profit decline was an increase in selling, general and administrative expenses, including research and development costs, which outpaced the increase in gross profit.
Segment Performance and Future Outlook
The prescription pharmaceuticals segment performed steadily, with growth driven by obstetrics and gynecology products 'Lelmina' and 'Droechi', as well as internal medicine products 'Thyroidine' and 'Refuxima'. The animal health segment also performed solidly, with sales up 1.0% year-over-year. The overseas business recorded sales of 324 million yen thanks to the contribution of newly consolidated subsidiary Hataphar. The full-year earnings guidance anticipates higher net sales of 71.0 billion yen and operating income of 6.0 billion yen, expecting both revenue and profit growth.
